Catalyst Pharmaceuticals, Inc. (CPRX)
USD 21.34
(-7.52%)
USD 21.34
(-7.52%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 259.42 Million USD | 190.95% |
| 2022 | 77.97 Million USD | 17.14% |
| 2021 | 66.56 Million USD | 9.61% |
| 2020 | 60.73 Million USD | 8.98% |
| 2019 | 55.72 Million USD | 55.67% |
| 2018 | 35.79 Million USD | 91.63% |
| 2017 | 18.67 Million USD | -3.11% |
| 2016 | 19.28 Million USD | -5.48% |
| 2015 | 20.39 Million USD | 39.8% |
| 2014 | 14.59 Million USD | 41.5% |
| 2013 | 10.31 Million USD | 97.5% |
| 2012 | 5.22 Million USD | -14.16% |
| 2011 | 6.08 Million USD | 34.77% |
| 2010 | 4.51 Million USD | -37.97% |
| 2009 | 7.27 Million USD | -33.22% |
| 2008 | 10.89 Million USD | 116.7% |
| 2007 | 5.02 Million USD | 73.21% |
| 2006 | 2.9 Million USD | 59.28% |
| 2005 | 1.82 Million USD | 235.6% |
| 2004 | 542.95 Thousand USD | 226.68% |
| 2003 | -428.61 Thousand USD | -267.46% |
| 2002 | 255.94 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 43.71 Million USD | -25.73% |
| 2024 Q1 | 58.86 Million USD | 33.76% |
| 2023 Q4 | 44 Million USD | -64.99% |
| 2023 FY | 226.86 Million USD | 190.95% |
| 2023 Q2 | 40.83 Million USD | 2.58% |
| 2023 Q3 | 125.7 Million USD | 207.82% |
| 2023 Q1 | 39.81 Million USD | 112.2% |
| 2022 Q3 | 22.47 Million USD | 32.99% |
| 2022 Q4 | 18.76 Million USD | -16.53% |
| 2022 Q1 | 19.83 Million USD | 8.86% |
| 2022 Q2 | 16.9 Million USD | -14.78% |
| 2022 FY | 77.97 Million USD | 17.14% |
| 2021 Q2 | 15.98 Million USD | 1.65% |
| 2021 Q1 | 15.72 Million USD | -10.29% |
| 2021 Q4 | 18.21 Million USD | 9.49% |
| 2021 FY | 66.56 Million USD | 9.61% |
| 2021 Q3 | 16.64 Million USD | 4.12% |
| 2020 Q3 | 13.73 Million USD | -9.54% |
| 2020 Q1 | 14.28 Million USD | -19.37% |
| 2020 FY | 60.73 Million USD | 8.98% |
| 2020 Q2 | 15.18 Million USD | 6.28% |
| 2020 Q4 | 17.52 Million USD | 27.62% |
| 2019 Q3 | 12.66 Million USD | -6.99% |
| 2019 FY | 55.72 Million USD | 55.67% |
| 2019 Q1 | 11.72 Million USD | -23.59% |
| 2019 Q2 | 13.61 Million USD | 16.14% |
| 2019 Q4 | 17.71 Million USD | 39.9% |
| 2018 Q2 | 6.33 Million USD | 6.78% |
| 2018 Q1 | 5.93 Million USD | 7.65% |
| 2018 FY | 35.79 Million USD | 91.63% |
| 2018 Q4 | 15.34 Million USD | 87.51% |
| 2018 Q3 | 8.18 Million USD | 29.15% |
| 2017 Q4 | 5.51 Million USD | 27.98% |
| 2017 FY | 18.67 Million USD | -3.11% |
| 2017 Q2 | 4.18 Million USD | -10.65% |
| 2017 Q1 | 4.67 Million USD | 8.48% |
| 2017 Q3 | 4.3 Million USD | 3.0% |
| 2016 Q4 | 4.31 Million USD | 10.22% |
| 2016 Q1 | 6.23 Million USD | 0.74% |
| 2016 Q3 | 3.91 Million USD | -18.7% |
| 2016 FY | 19.28 Million USD | -5.48% |
| 2016 Q2 | 4.81 Million USD | -22.81% |
| 2015 Q4 | 6.19 Million USD | 23.4% |
| 2015 Q1 | 4.29 Million USD | 7.73% |
| 2015 Q2 | 4.89 Million USD | 14.11% |
| 2015 FY | 20.39 Million USD | 39.8% |
| 2015 Q3 | 5.01 Million USD | 2.45% |
| 2014 Q2 | 2.99 Million USD | -14.77% |
| 2014 FY | 14.59 Million USD | 41.5% |
| 2014 Q4 | 3.98 Million USD | -3.05% |
| 2014 Q3 | 4.1 Million USD | 37.42% |
| 2014 Q1 | 3.5 Million USD | 29.61% |
| 2013 FY | 10.31 Million USD | 97.5% |
| 2013 Q1 | 1.7 Million USD | 13.29% |
| 2013 Q2 | 2.65 Million USD | 55.59% |
| 2013 Q3 | 3.24 Million USD | 22.32% |
| 2013 Q4 | 2.7 Million USD | -16.6% |
| 2012 Q4 | 1.5 Million USD | 17.27% |
| 2012 Q1 | 1.36 Million USD | -32.92% |
| 2012 Q3 | 1.28 Million USD | 20.27% |
| 2012 FY | 5.22 Million USD | -14.16% |
| 2012 Q2 | 1.06 Million USD | -21.79% |
| 2011 Q4 | 2.03 Million USD | 79.88% |
| 2011 FY | 6.08 Million USD | 34.77% |
| 2011 Q2 | 1.39 Million USD | -8.02% |
| 2011 Q1 | 1.51 Million USD | 24.41% |
| 2011 Q3 | 1.13 Million USD | -19.07% |
| 2010 FY | 4.51 Million USD | -37.97% |
| 2010 Q3 | 908.46 Thousand USD | -31.85% |
| 2010 Q2 | 1.33 Million USD | 26.92% |
| 2010 Q1 | 1.05 Million USD | -10.2% |
| 2010 Q4 | 1.22 Million USD | 34.42% |
| 2009 Q2 | 1.76 Million USD | -41.9% |
| 2009 Q3 | 1.29 Million USD | -26.94% |
| 2009 Q4 | 1.16 Million USD | -9.49% |
| 2009 FY | 7.27 Million USD | -33.22% |
| 2009 Q1 | 3.04 Million USD | -19.7% |
| 2008 Q4 | 3.79 Million USD | 30.08% |
| 2008 Q3 | 2.91 Million USD | 18.31% |
| 2008 Q2 | 2.46 Million USD | 42.9% |
| 2008 Q1 | 1.72 Million USD | 50.89% |
| 2008 FY | 10.89 Million USD | 116.7% |
| 2007 FY | 5.02 Million USD | 73.21% |
| 2007 Q3 | 950.42 Thousand USD | -33.86% |
| 2007 Q4 | 1.14 Million USD | 20.22% |
| 2007 Q2 | 1.43 Million USD | -4.02% |
| 2007 Q1 | 1.49 Million USD | 69.14% |
| 2006 Q3 | 1.34 Million USD | 297.72% |
| 2006 Q2 | 337.47 Thousand USD | 201.22% |
| 2006 FY | 2.9 Million USD | 59.28% |
| 2006 Q1 | -333.41 Thousand USD | 74.77% |
| 2006 Q4 | 885.15 Thousand USD | -34.05% |
| 2005 Q3 | -241.85 Thousand USD | 63.4% |
| 2005 FY | 1.82 Million USD | 235.6% |
| 2005 Q4 | -1.32 Million USD | -446.48% |
| 2005 Q2 | -660.83 Thousand USD | 0.0% |
| 2005 Q1 | -660.83 Thousand USD | -389.67% |
| 2004 Q3 | -134.95 Thousand USD | 0.0% |
| 2004 Q2 | -134.95 Thousand USD | 0.0% |
| 2004 FY | 542.95 Thousand USD | 226.68% |
| 2004 Q1 | -134.95 Thousand USD | 0.0% |
| 2004 Q4 | -134.95 Thousand USD | 0.0% |
| 2003 FY | -428.61 Thousand USD | -267.46% |
| 2002 FY | 255.94 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 5.743% |
| Alkermes plc | 996.24 Million USD | 73.96% |
| Agenus Inc. | 78.18 Million USD | -231.818% |
| Aptorum Group Limited | 10.56 Thousand USD | -2455181.09% |
| Ardelyx, Inc. | 169.93 Million USD | -52.66% |
| Dyadic International, Inc. | 9.15 Million USD | -2734.411% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1065.798% |
| Lantern Pharma Inc. | 17.87 Million USD | -1351.12% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3753.642% |
| Novavax, Inc. | 779.12 Million USD | 66.703% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -220.033% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -215.618% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1235.967% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -776.258% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -388.317% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 31.819% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -967.302% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -585.059% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -743.083% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -206.229% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1386.08% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -54.02% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -692.985% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -62.357% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 85.588% |
| AlloVir, Inc. | 180.93 Million USD | -43.382% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 41.799% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -774.015% |
| Bicycle Therapeutics plc | 216.92 Million USD | -19.594% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -50.914% |
| ChromaDex Corporation | 56.37 Million USD | -360.145% |
| Chimerix, Inc. | 93.38 Million USD | -177.79% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1765.073% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -72.334% |
| CRISPR Therapeutics AG | 463.49 Million USD | 44.028% |
| Precision BioSciences, Inc. | 92.46 Million USD | -180.572% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -2.118% |
| Fortress Biotech, Inc. | 200.19 Million USD | -29.586% |
| Fortress Biotech, Inc. | 200.19 Million USD | -29.586% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -692.234% |
| ImmuCell Corporation | 9.61 Million USD | -2597.465% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -64.387% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1507.231% |
| Incyte Corporation | 1.19 Billion USD | 78.209% |
| Innoviva, Inc. | 132.15 Million USD | -96.305% |
| IO Biotech, Inc. | 91.44 Million USD | -183.701% |
| Jaguar Health, Inc. | 42.01 Million USD | -517.458% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -53.255% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -207.656% |
| ContextLogic Inc. | 387 Million USD | 32.965% |
| MiMedx Group, Inc. | 229.72 Million USD | -12.928% |
| MEI Pharma, Inc. | 34.78 Million USD | -645.796% |
| NextCure, Inc. | 67.63 Million USD | -283.555% |
| Onconetix, Inc. | 34.9 Million USD | -643.18% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1935.344% |
| Opthea Limited | 191.96 Million USD | -35.14% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -9328.202% |
| Vaxcyte, Inc. | 468.04 Million USD | 44.572% |
| PDS Biotechnology Corporation | 43.04 Million USD | -502.68% |
| Precigen, Inc. | 84.18 Million USD | -208.175% |
| Pharming Group N.V. | 225.49 Million USD | -15.049% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -54.579% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -257.502% |
| PureTech Health plc | 144.59 Million USD | -79.412% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -99.155% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -5.82% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -967.302% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -13.445% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -740.679% |
| Acelyrin, Inc. | 422.06 Million USD | 38.534% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -2011882.317% |
| Summit Therapeutics Inc. | 87.68 Million USD | -195.857% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -599.938% |
| Senti Biosciences, Inc. | 94.7 Million USD | -173.93% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -109.971% |
| Elevation Oncology, Inc. | 45.44 Million USD | -470.855% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -780.332% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -6480.97% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -96.274% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -661.112% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2969.755% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -43.091% |
| Seer, Inc. | 110.49 Million USD | -134.795% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -267.489% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -177.525% |
| ESSA Pharma Inc. | 32.13 Million USD | -707.32% |
| GlycoMimetics, Inc. | 39.28 Million USD | -560.362% |
| GT Biopharma, Inc. | 13.57 Million USD | -1810.909% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -18.012% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -28.993% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -357.064% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -379.706% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2510.528% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 35.716% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1270.516% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -411.757% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 0.09% |
| Aptose Biosciences Inc. | 52.35 Million USD | -395.502% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1700.266% |
| Soligenix, Inc. | 7.79 Million USD | -3227.988% |
| Century Therapeutics, Inc. | 56.07 Million USD | -362.672% |
| Kura Oncology, Inc. | 165.8 Million USD | -56.465% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -126.558% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -3018.464% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -10353.777% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -140.882% |
| Autolus Therapeutics plc | 196.72 Million USD | -31.871% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -206.442% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -122.772% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1238.415% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 19.373% |
| GRI Bio, Inc. | 11.33 Million USD | -2189.718% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3576.814% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -97.743% |
| IGM Biosciences, Inc. | 265.59 Million USD | 2.322% |
| INmune Bio, Inc. | 29.89 Million USD | -767.758% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -50.344% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -543.506% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1523.5% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1548.027% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -317.767% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -141.276% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 5.901% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 13.941% |
| Verastem, Inc. | 92.08 Million USD | -181.726% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1346.151% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -39.682% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -113.682% |
| Histogen Inc. | 14.27 Million USD | -1717.72% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1516.542% |
| Surrozen, Inc. | 18.55 Million USD | -1298.518% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1639.356% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4996.522% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -334.743% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -911.522% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -451.898% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -3298.799% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -45.633% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -435.472% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -5.886% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1588.242% |
| Apollomics, Inc. | 54.14 Million USD | -379.174% |
| Amarin Corporation plc | 272.35 Million USD | 4.748% |
| Mesoblast Limited | 5.9 Million USD | -4295.544% |
| Turnstone Biologics Corp. | 78.33 Million USD | -231.161% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -6.269% |
| Synaptogenix, Inc. | 8.31 Million USD | -3020.394% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1678.589% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -2.517% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -678.351% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2837.585% |
| Exelixis, Inc. | 1.58 Billion USD | 83.651% |
| Better Therapeutics, Inc. | 38.26 Million USD | -578.023% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -11.797% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 69.665% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2097.202% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -3125.914% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -764.952% |
| Gritstone bio, Inc. | 148.37 Million USD | -74.845% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -276.737% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1485.706% |
| Avid Bioservices, Inc. | 25.99 Million USD | -897.942% |
| Insmed Incorporated | 949.26 Million USD | 72.671% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1553.464% |
| MediWound Ltd. | 18.86 Million USD | -1274.947% |
| OmniAb, Inc. | 83.89 Million USD | -209.226% |
| Alector, Inc. | 248.8 Million USD | -4.27% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -10.72% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -396.498% |
| Zai Lab Limited | 547.47 Million USD | 52.614% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 34.925% |
| Aura Biosciences, Inc. | 84.99 Million USD | -205.238% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -4.972% |
| Immunic, Inc. | 99.22 Million USD | -161.457% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -63.148% |
| Veracyte, Inc. | 357.93 Million USD | 27.521% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.123% |
| FibroGen, Inc. | 398.11 Million USD | 34.836% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1725.651% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3666.362% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -3540.679% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 92.031% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -902.686% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 18.044% |
| TG Therapeutics, Inc. | 198.47 Million USD | -30.709% |
| Galecto, Inc. | 35.62 Million USD | -628.17% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -537.58% |
| Fortrea Holdings Inc. | 457.3 Million USD | 43.27% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -377.956% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -798.348% |
| XBiotech Inc. | 37.51 Million USD | -591.616% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -276.737% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1156.356% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -82.615% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -161.847% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -134.316% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 72.927% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -799.376% |
| Vaxxinity, Inc. | 56.05 Million USD | -362.837% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 39.758% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1062.907% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -133.997% |
| NexImmune, Inc. | 28.16 Million USD | -821.008% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -4590.426% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1349.908% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 90.785% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -918.991% |
| Scopus BioPharma Inc. | 11.71 Million USD | -2114.492% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -104.172% |
| Ainos, Inc. | 12.95 Million USD | -1902.87% |
| Pluri Inc. | 22.48 Million USD | -1054.026% |
| Prothena Corporation plc | 282.4 Million USD | 8.138% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -29.698% |
| Celularity Inc. | 215.05 Million USD | -20.63% |
| Rallybio Corporation | 78.93 Million USD | -228.669% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1227.525% |
| MeiraGTx Holdings plc | 151.07 Million USD | -71.716% |
| Omeros Corporation | 94.75 Million USD | -173.797% |
| Humacyte, Inc. | 23.49 Million USD | -1004.077% |
| Immunocore Holdings plc | 308.04 Million USD | 15.782% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -7552.655% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -198.653% |
| Blueprint Medicines Corporation | 722.86 Million USD | 64.111% |
| CalciMedica, Inc. | 21.81 Million USD | -1089.096% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -247.475% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -61.595% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -51.449% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 12.041% |
| Pulmatrix, Inc. | 22.03 Million USD | -1077.171% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -650.325% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -191.928% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 52.966% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -257.576% |
| Cytokinetics, Incorporated | 173.61 Million USD | -49.428% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -653.726% |
| Nutriband Inc. | 5.73 Million USD | -4424.304% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -494.834% |
| Vor Biopharma Inc. | 126.03 Million USD | -105.834% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 78.185% |
| Evogene Ltd. | 27.79 Million USD | -833.519% |
| ProKidney Corp. | 151.52 Million USD | -71.213% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -249.747% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -3272.554% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 57.764% |
| CorMedix Inc. | 48.95 Million USD | -429.895% |
| BioLineRx Ltd. | 50.8 Million USD | -410.659% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -72.147% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -581.406% |
| Atai Life Sciences N.V. | 125.78 Million USD | -106.245% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -217.77% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -218.669% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -2.721% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -692.379% |
| MediciNova, Inc. | 10.9 Million USD | -2279.988% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -101.386% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3473.581% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4207.83% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 45.54% |
| Biomea Fusion, Inc. | 126.13 Million USD | -105.672% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 80.224% |
| Mereo BioPharma Group plc | 35.84 Million USD | -623.802% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -35.761% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -12.816% |
| Absci Corporation | 73.66 Million USD | -252.164% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -840.559% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -94.195% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -7.129% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 1.001% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -24.727% |
| Allakos Inc. | 196.05 Million USD | -32.322% |
| Imunon, Inc. | 20.31 Million USD | -1177.3% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -128.631% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 29.621% |
| BioAtla, Inc. | 129.68 Million USD | -100.039% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2097.202% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1537.474% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -205.501% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -521.258% |
| XOMA Corporation | 46.46 Million USD | -458.348% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -133.357% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -82.1% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1898.806% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -150.275% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -50.069% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -1.83% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -593.501% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -3054.175% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1443.645% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -11308.462% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 13.328% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3755.482% |
| UroGen Pharma Ltd. | 138.88 Million USD | -86.787% |
| Sutro Biopharma, Inc. | 243 Million USD | -6.755% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -3466.165% |
| Orgenesis Inc. | 45.75 Million USD | -466.962% |
| Entera Bio Ltd. | 8.86 Million USD | -2828.047% |
| GH Research PLC | 41.22 Million USD | -529.336% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -909.122% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -212.361% |
| Xencor, Inc. | 306.97 Million USD | 15.49% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -5158.324% |
| Replimune Group, Inc. | 234.77 Million USD | -10.5% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1166.112% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -35.261% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3755.482% |
| Portage Biotech Inc. | 18.19 Million USD | -1325.49% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3473.581% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -147.163% |
| OncoCyte Corporation | 25.63 Million USD | -911.916% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -4155.934% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -2164.324% |
| Purple Biotech Ltd. | -22.46 Million USD | 1254.694% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1474.181% |
| scPharmaceuticals Inc. | 65.17 Million USD | -298.025% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2969.125% |
| HilleVax, Inc. | 133.34 Million USD | -94.552% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2422.363% |
| Tharimmune, Inc. | 9.45 Million USD | -2643.723% |
| Genprex, Inc. | 31.06 Million USD | -735.223% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -38.341% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -726.8% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -33811.765% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -4662.784% |
| OKYO Pharma Limited | 8243.57 USD | -3146898.206% |
| Savara Inc. | 15.74 Million USD | -1547.666% |
| Curis, Inc. | 58.35 Million USD | -344.563% |
| Daré Bioscience, Inc. | 33.6 Million USD | -671.882% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4994.268% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -3377.081% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -860.051% |
| BeiGene, Ltd. | 3.28 Billion USD | 92.107% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1201.074% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 47.987% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -68.839% |
| Erasca, Inc. | 141.52 Million USD | -83.307% |
| bluebird bio, Inc. | 240.23 Million USD | -7.989% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5630.649% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 85.144% |
| DBV Technologies S.A. | 92.16 Million USD | -181.494% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5630.649% |
| Moderna, Inc. | 6.39 Billion USD | 95.943% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -508.85% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1705.826% |
| Molecular Templates, Inc. | 63.09 Million USD | -311.192% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -288.937% |
| Travere Therapeutics, Inc. | 472 Million USD | 45.037% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -81.022% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -317.875% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -497.561% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -24.646% |
| MacroGenics, Inc. | 217.21 Million USD | -19.432% |
| RenovoRx, Inc. | 11.39 Million USD | -2176.457% |
| Adicet Bio, Inc. | 152.03 Million USD | -70.632% |
| Prime Medicine, Inc. | 186.63 Million USD | -38.998% |
| Aditxt, Inc. | 25.95 Million USD | -899.682% |
| Adagene Inc. | 41.83 Million USD | -520.169% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3448.858% |
| Quantum-Si incorporated | 111.65 Million USD | -132.337% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -50.96% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1679.593% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -624.206% |
| SciSparc Ltd. | 9.01 Million USD | -2778.981% |
| Vericel Corporation | 142.04 Million USD | -82.642% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2896.824% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1023.607% |
| Generation Bio Co. | 144.46 Million USD | -79.574% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -212.447% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -200.052% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 12.273% |
| Invivyd, Inc. | 205.75 Million USD | -26.084% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -259.519% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2666.166% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -244.733% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2421.872% |
| 2seventy bio, Inc. | 289.88 Million USD | 10.508% |
| ADMA Biologics, Inc. | 66.58 Million USD | -289.609% |
| Clene Inc. | 41.07 Million USD | -531.619% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1925.51% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -373.438% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4207.83% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 26.31% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -606.264% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -669.168% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -150.164% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -696.051% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -52.354% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 66.208% |
| Evaxion Biotech A/S | 22.27 Million USD | -1064.908% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -91.395% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -10.449% |
| Trevena, Inc. | 38.41 Million USD | -575.357% |
| Surrozen, Inc. | 18.55 Million USD | -1298.518% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -224.504% |
| Cingulate Inc. | 22.75 Million USD | -1039.869% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3562.694% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -480.798% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -3050.678% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -152.954% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 65.597% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -317.929% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2867.791% |
| Kronos Bio, Inc. | 128.11 Million USD | -102.489% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -208.575% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -8745.084% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -157.297% |
| Statera Biopharma, Inc. | 28.82 Million USD | -799.859% |
| ImmunityBio, Inc. | 362.87 Million USD | 28.508% |
| Korro Bio, Inc. | 84.53 Million USD | -206.888% |
| Kineta, Inc. | 21.15 Million USD | -1126.248% |
| BioVie Inc. | 31.95 Million USD | -711.967% |
| Codexis, Inc. | 66.51 Million USD | -290.007% |
| Celularity Inc. | 215.05 Million USD | -20.63% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -14.475% |
| Celcuity Inc. | 66.23 Million USD | -291.701% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3862.464% |
| Cibus, Inc. | 320.3 Million USD | 19.007% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -503.314% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -666.532% |
| IN8bio, Inc. | 30.33 Million USD | -755.144% |
| Kodiak Sciences Inc. | 277.32 Million USD | 6.453% |
| Annexon, Inc. | 143.72 Million USD | -80.503% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -103.325% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1032.415% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -40435.156% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 66.723% |
| Eyenovia, Inc. | 25.4 Million USD | -921.099% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -84.888% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4564.239% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -227.834% |
| Arcellx, Inc. | 200.19 Million USD | -29.584% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -465.196% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -19.876% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2505.453% |
| Moolec Science SA | 52.75 Million USD | -391.795% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -324.327% |
| Geron Corporation | 70.44 Million USD | -268.287% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -457.424% |
| Royalty Pharma plc | 862.4 Million USD | 69.918% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -175.773% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2681.183% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1046.451% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -24.836% |
| Humacyte, Inc. | 23.49 Million USD | -1004.077% |
| Structure Therapeutics Inc. | 102.77 Million USD | -152.42% |
| 89bio, Inc. | 151.2 Million USD | -71.573% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -223.747% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1684.216% |
| Genelux Corporation | 24.33 Million USD | -966.057% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -664.747% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -50.07% |
| Notable Labs, Ltd. | 14.77 Million USD | -1656.432% |
| Liquidia Corporation | 87.98 Million USD | -194.855% |
| Mustang Bio, Inc. | 48.5 Million USD | -434.886% |
| Immunovant, Inc. | 282.7 Million USD | 8.236% |
| Quantum-Si incorporated | 111.65 Million USD | -132.337% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1050.75% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1119.848% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -154.308% |
| Acasti Pharma Inc. | 11.3 Million USD | -2195.593% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1031.817% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1523.5% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -457.4% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -22765.289% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1533.042% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -789.752% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -526.873% |
| PepGen Inc. | 84.76 Million USD | -206.048% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -775.519% |
| United Therapeutics Corporation | 885.1 Million USD | 70.69% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1033.009% |
| Solid Biosciences Inc. | 104.31 Million USD | -148.694% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -692.73% |
| Immuneering Corporation | 58.41 Million USD | -344.123% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4996.522% |
| Silo Pharma, Inc. | 3.92 Million USD | -6514.853% |
| Belite Bio, Inc | 31.66 Million USD | -719.202% |
| XOMA Corporation | 46.46 Million USD | -458.348% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -284.049% |
| Bionomics Limited | 17.89 Billion USD | 98.55% |
| Apogee Therapeutics, Inc. | 93 Million USD | -178.943% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 827.088% |
| uniQure N.V. | 285.08 Million USD | 9.001% |
| Cassava Sciences, Inc. | 105.95 Million USD | -144.84% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3448.858% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -33.582% |
| Forte Biosciences, Inc. | 32.47 Million USD | -698.796% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -3022.309% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -782.548% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4564.239% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1725.651% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2818.495% |
| Altimmune, Inc. | 30.55 Million USD | -749.015% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 39.337% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 827.088% |
| Compugen Ltd. | 43.97 Million USD | -489.991% |
| Peak Bio, Inc. | 1249.13 USD | -20768354.845% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -250.007% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1059.079% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -6.676% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -808.892% |
| Zura Bio Limited | 62.63 Million USD | -314.166% |
| PolyPid Ltd. | 21.04 Million USD | -1132.716% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1493.911% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -808.892% |
| Instil Bio, Inc. | 85.78 Million USD | -202.413% |
| argenx SE | 1.53 Billion USD | 83.083% |
| Immunome, Inc. | 122.82 Million USD | -111.224% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -435.195% |
| Verona Pharma plc | 67.15 Million USD | -286.329% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -902.221% |
| Shattuck Labs, Inc. | 93.61 Million USD | -177.122% |
| CervoMed Inc. | 14.95 Million USD | -1634.383% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -266.922% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2936.341% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -408.676% |
| Moolec Science SA | 52.75 Million USD | -391.795% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1477.201% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -95.711% |
| AnaptysBio, Inc. | 181.56 Million USD | -42.88% |
| Design Therapeutics, Inc. | 78.19 Million USD | -231.788% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -198.049% |
| NeurAxis, Inc. | 8.82 Million USD | -2840.927% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1961.383% |
| Lumos Pharma, Inc. | 38.66 Million USD | -570.956% |
| Achilles Therapeutics plc | 75.25 Million USD | -244.728% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -902.221% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1824.875% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -878.872% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -8745.084% |
| Nutriband Inc. | 5.73 Million USD | -4424.304% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -134.18% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -366.147% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -409.886% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -292.479% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -379.324% |
| Palisade Bio, Inc. | 13.32 Million USD | -1847.635% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -471.307% |
| Beam Therapeutics Inc. | 554.19 Million USD | 53.189% |
| Neurogene Inc. | 55.58 Million USD | -366.734% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -4.401% |
| AEON Biopharma, Inc. | 48.42 Million USD | -435.681% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -168.25% |
| Sesen Bio, Inc. | 78.38 Million USD | -230.979% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -210.581% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1961.072% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 42.477% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -195.17% |
| Athira Pharma, Inc. | 125.46 Million USD | -106.769% |
| Vaccinex, Inc. | 23.45 Million USD | -1006.054% |
| HCW Biologics Inc. | 21.02 Million USD | -1133.74% |
| XOMA Corporation | 46.46 Million USD | -458.348% |
| Nektar Therapeutics | 190.9 Million USD | -35.894% |
| Arvinas, Inc. | 480 Million USD | 45.953% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -11308.462% |
| Merus N.V. | 200.49 Million USD | -29.393% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -151.004% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -649.35% |
| Rezolute, Inc. | 70.38 Million USD | -268.569% |
| Clene Inc. | 41.07 Million USD | -531.619% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1483.939% |
| BeyondSpring Inc. | 24.86 Million USD | -943.334% |
| Synlogic, Inc. | 58.53 Million USD | -343.219% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1349.95% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -5675.267% |
| Peak Bio, Inc. | 1249.13 USD | -20768354.845% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -329.185% |
| Krystal Biotech, Inc. | 160.42 Million USD | -61.71% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 4.141% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 25.461% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -11928.604% |
| MannKind Corporation | 125.59 Million USD | -106.554% |
| Ikena Oncology, Inc. | 84.57 Million USD | -206.732% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2589.178% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -189.534% |
| Gossamer Bio, Inc. | 183.75 Million USD | -41.177% |
| CohBar, Inc. | 12.38 Million USD | -1994.114% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -411.444% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -840.559% |
| Legend Biotech Corporation | 583.14 Million USD | 55.513% |
| Mural Oncology plc | 192.07 Million USD | -35.067% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -286.354% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1506.817% |
| Disc Medicine, Inc. | 91.12 Million USD | -184.691% |
| Champions Oncology, Inc. | 28.11 Million USD | -822.892% |
| REGENXBIO Inc. | 321.15 Million USD | 19.222% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4738.905% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -365.286% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -565.864% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -126.855% |
| Vaxart, Inc. | 90.72 Million USD | -185.943% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2944.892% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -506.217% |
| Cellectis S.A. | 97.32 Million USD | -166.569% |
| Longeveron Inc. | 21.25 Million USD | -1120.824% |
| Repare Therapeutics Inc. | 167.35 Million USD | -55.013% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 80.936% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -242.951% |
| Revolution Medicines, Inc. | 498.76 Million USD | 47.987% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3799.955% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -490.219% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -247.801% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -272.55% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -2245.615% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.567% |
| Denali Therapeutics Inc. | 527.23 Million USD | 50.795% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2896.824% |
| Veru Inc. | 101.34 Million USD | -155.974% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1008.322% |
| Cingulate Inc. | 22.75 Million USD | -1039.869% |
| Passage Bio, Inc. | 108.38 Million USD | -139.346% |
| Context Therapeutics Inc. | 25.07 Million USD | -934.695% |
| Exicure, Inc. | 14.07 Million USD | -1743.031% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -25.895% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -499.12% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2726.815% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -2.749% |
| Nuvalent, Inc. | 149.49 Million USD | -73.538% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -3115.919% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -150.289% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1109.497% |
| OmniAb, Inc. | 83.89 Million USD | -209.226% |
| Anew Medical, Inc. | 1.3 Million USD | -19842.868% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -691.799% |
| Lipocine Inc. | 15.08 Million USD | -1620.309% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -278.651% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -240.667% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -543.506% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -125.895% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1058.975% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 60.938% |
| Ocugen, Inc. | 71.56 Million USD | -262.492% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -176.378% |
| Q32 Bio Inc. | 92.68 Million USD | -179.915% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1125.205% |
| Alumis Inc. Common Stock | 158.17 Million USD | -64.012% |
| Equillium, Inc. | 50.6 Million USD | -412.637% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -315.705% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1765.621% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1275.158% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -452.544% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -139.176% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1993.365% |
| Dominari Holdings Inc. | 23.83 Million USD | -988.42% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2712.879% |
| vTv Therapeutics Inc. | 11.9 Million USD | -2078.76% |
| Bio-Techne Corporation | 563.03 Million USD | 53.924% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 36.541% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 3.472% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -96.123% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1700.187% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -58.48% |
| Nkarta, Inc. | 131.65 Million USD | -97.057% |
| BioCardia, Inc. | 12.12 Million USD | -2040.294% |
| Iterum Therapeutics plc | 47.46 Million USD | -446.526% |